Clinical Trials Logo

Lymphoma, Follicular clinical trials

View clinical trials related to Lymphoma, Follicular.

Filter by:

NCT ID: NCT03583424 Active, not recruiting - Clinical trials for Recurrent Grade 1 Follicular Lymphoma

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Start date: September 10, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow.

NCT ID: NCT03568461 Active, not recruiting - Follicular Lymphoma Clinical Trials

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

ELARA
Start date: November 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.

NCT ID: NCT03479268 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Start date: March 22, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03436602 Active, not recruiting - Follicular Lymphoma Clinical Trials

Personalized Risk Stratification Model of Follicular Lymphoma Patients

Start date: March 1, 2018
Phase:
Study type: Observational

The study aims at developping and validating an integrated clinico-molecular model for an accurate identification of FL patients who are progression free and progressed, respectively, at 24 months after treatment.

NCT ID: NCT03410901 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Start date: April 9, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of the anti-OX40 antibody BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating patients with low-grade B-cell Non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. Anti-OX40 antibody is a monoclonal antibody that enhances the activation of T cells, immune cells that are important for fighting tumors Radiation therapy uses high energy x-rays to kill cancer cells and may make them more easily detected by the immune system. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS 986178 and radiation therapy may work better in treating patients with low-grade B-cell non-hodgkin lymphomas.

NCT ID: NCT03401853 Active, not recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Start date: March 23, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab with rituximab or obinutuzumab work in treating patients with follicular lymphoma or diffuse large B cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Rituximab and obinutuzumab are monoclonal antibodies. They bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving pembrolizumab with rituximab or obinutuzumab may help kill more cancer cells in patients with follicular lymphoma or diffuse large B cell lymphoma.

NCT ID: NCT03361852 Active, not recruiting - Follicular Lymphoma Clinical Trials

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Start date: March 14, 2022
Phase: Phase 1
Study type: Interventional

This research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: - Rituximab - Personalized NeoAntigen vaccine - Poly-ICLC - Pembrolizumab

NCT ID: NCT03341520 Active, not recruiting - Clinical trials for Stage II Follicular Lymphoma Grade 2

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

GAZAI
Start date: April 24, 2018
Phase: Phase 2
Study type: Interventional

Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders. Primary Objective: Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy in combination with Gazyvaro (Obinutuzumab) in early stage nodal follicular lymphoma in order to avoid conventional full dose IF radiotherapy. Secondary Objective: Efficacy and safety of a response adapted radiation dose treatment schedule.

NCT ID: NCT03332017 Active, not recruiting - Clinical trials for Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

ROSEWOOD
Start date: November 14, 2017
Phase: Phase 2
Study type: Interventional

he purpose of the study is to evaluate the efficacy, safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.

NCT ID: NCT03277729 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Start date: December 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment (refractory).